Comparative effectiveness of Tamsulosin and Tadalafil therapy in ureteral stents-related symptoms (uSRS)
Abstract
Introduction: Lower Urinary Tract Symptoms (LUTS) can be a complication of ureteral stent insertion. Clinically, PDE5 inhibitors (Tadalafil) and alpha blockers (Tamsulosin) are the preferred drugs for treating lower urinary tract symptoms after ureteral stent insertion, also called ureteral stents-related symptoms (uSRS). This study aims to compare the effectiveness of 0.4 mg/day Tamsulosin and 10 mg/day Tadalafil for treating uSRS. Methods: This study used a double-blinded experimental design. Fifty patients with uSRS were randomly assigned to one of 2 groups; group I (n = 25) received 10 mg/day Tadalafil, while group II (n = 25) received 0.4 mg/day Tamsulosin. The Ureteral Symptoms Score Questionnaire (USSQ) was administered on the 7th, 14th, 21st, and 28th day after insertion of the ureteral stent. p values of <0.05 were considered to be statistically significant. Results: The administration of 10 mg/day Tadalafil had a good effect in reducing the LUTS score: mean scores were VS = 11.03, p = 4.21, GC = 3.8, WA= 1.29, SA= 1.94, and AS = 3.21. The administration of 0.4 mg/day Tamsulosin also had a good effect in reducing the LUTS score: mean scores were VS = 13.73, p = 9.89, GC = 3.85, WA= 4.31, SA= 0.59, and AS = 4.69. Conclusion: Administration of 10 mg/day Tadalafil had significantly better results compared to 0.4 mg/day Tamsulosin in improving uSRS, except in VS week 2 and in GC weeks 2 and 4.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 25 participants or records.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.